Alexion Pharmaceuticals Inc (ALXN)

142.87
0.04 0.03
NASDAQ : Health Care
Prev Close 142.83
Open 142.66
Day Low/High 141.92 / 143.51
52 Wk Low/High 110.56 / 205.29
Volume 1.32M
Avg Volume 1.76M
Exchange NASDAQ
Shares Outstanding 223.19M
Market Cap 32.06B
EPS 1.80
P/E Ratio 62.18
Div & Yield N.A. (N.A)

Latest News

Alexion Could Target Sage, Ra Pharma: Analyst

Alexion Could Target Sage, Ra Pharma: Analyst

BMO Capital Markets analyst M. Ian Somaiya says Alexion could view Sage Therapeutics and Ra Pharmaceuticals as potential acquisition targets. Somaiya pointed to Sage's diverse pipeline and Ra's diversified complement pipeline.

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

The Dow, S&P 500 and Nasdaq score new records on Tuesday, Sept. 12, as the promise of tax reform fuels gains in the financials sector.

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Stocks returned to session highs as Apple Inc. lays out its latest product launches, including a new version of its smartwatch and iPhone. Here's where stocks are trading Tuesday afternoon.

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Stocks edged higher in cautious gains after Monday's rally pulled the Dow Jones Industrial Average and S&P 500 to their best gains in six months.

Stocks Come Off Highs as Apple Wait Counters Boost From Tax Reform Talk

Stocks Come Off Highs as Apple Wait Counters Boost From Tax Reform Talk

Stocks come off of highs on Tuesday, Sept. 12, as a tech sector in wait-and-see mode countered gains in the financial sector. Here's where stocks are trading at market open on Tuesday.

Alexion Pharmaceuticals Slashes 20% of Its Workforce So It Could Boost Profits

Alexion Pharmaceuticals Slashes 20% of Its Workforce So It Could Boost Profits

The resulting financial flexibility will allow Alexion to reinvest $100 million per year in R&D.

Alexion Announces Restructuring To Advance Corporate Strategy

Alexion Announces Restructuring To Advance Corporate Strategy

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced an operational plan to re-align the global organization with its refocused corporate strategy.

Alexion To Host Call To Discuss Restructuring To Advance Corporate Strategy At 8:30 A.m. On September 12, 2017

Alexion To Host Call To Discuss Restructuring To Advance Corporate Strategy At 8:30 A.m. On September 12, 2017

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that the Company will issue a press release on its restructuring to advance its corporate strategy on Tuesday, September 12, 2017 at 8:00 a.

Alexion To Present At Upcoming Investor Conferences

Alexion To Present At Upcoming Investor Conferences

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that management will present at two upcoming investor conferences: Morgan Stanley 15th Annual Global Healthcare Conference in New York on Tuesday,...

Alexion Pharmaceuticals Becomes #31 Most Shorted Nasdaq 100 Component, Replacing Paychex

Alexion Pharmaceuticals Becomes #31 Most Shorted Nasdaq 100 Component, Replacing Paychex

The most recent short interest data has been released for the 08/15/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Rally May Soon Hit a Wall

D.C. drama has been quiet -- too quiet.

Alexion Receives Three New U.S. Patents For Soliris® (eculizumab), Extending Patent Protection Into 2027

Alexion Receives Three New U.S. Patents For Soliris® (eculizumab), Extending Patent Protection Into 2027

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the United States Patent and Trademark Office (USPTO) has issued U.

Achillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence

Achillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence

Thursday's downgrade is in part based on a lack of confidence in Achillion's CH-4471 to compete with Alexion Pharmaceuticals' Soliris treatment.

Alexion And Sema4 Partner In Rare Disease Diagnostics And Systems Biology

Alexion And Sema4 Partner In Rare Disease Diagnostics And Systems Biology

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Sema4 today announced a strategic partnership to leverage their shared experience in data science and systems biology to accelerate rare disease diagnosis and therapeutic...

Alexion Spikes on Q2 Earnings Blowout Providing Positive Signs for Rest of Sector -Biotech Movers

Alexion Spikes on Q2 Earnings Blowout Providing Positive Signs for Rest of Sector -Biotech Movers

Alexion Pharmaceuticals, United Therapeutics and Gilead Sciences were among the biotech stock movers in premarket trading on July 27.

Alexion Reports Second Quarter 2017 Results

Alexion Reports Second Quarter 2017 Results

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the second quarter of 2017.

Alexion Pharmaceuticals Takes Over #120 Spot From Range Resources

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Alexion Pharmaceuticals Inc. has taken over the #120 spot from Range Resources Corp , according to ETF Channel.

Can Alexion Pharamaceuticals See an Upside Breakout?

Can Alexion Pharamaceuticals See an Upside Breakout?

A quantitative upgrade and chart patterns may do the trick.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALXN Downgrades: EBAY, RMP Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

How Competition Drives Stocks Nowhere: Cramer's 'Mad Money' Recap (Tuesday 7/11/17)

How Competition Drives Stocks Nowhere: Cramer's 'Mad Money' Recap (Tuesday 7/11/17)

'Blind side' competition is playing havoc with some highly visible companies, says Jim Cramer. You can't compete with free.

Alexion Pharmaceuticals, Incyte, Walt Disney: 'Mad Money' Lightning Round

Alexion Pharmaceuticals, Incyte, Walt Disney: 'Mad Money' Lightning Round

Jim Cramer's bullish on Alexion Pharmaceuticals and Incyte. But, he says, Disney's good for the long term.

Alexion To Report Second Quarter 2017 Results And Strategic Update On Thursday, July 27, 2017

Alexion To Report Second Quarter 2017 Results And Strategic Update On Thursday, July 27, 2017

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the second quarter 2017 on Thursday, July 27, 2017 before the US financial markets open.

Alexion Investigation Believed to Have 'Minimal Impact'

Alexion Investigation Believed to Have 'Minimal Impact'

Investors shouldn't ruffle their feathers. At least, not yet.

Biotech Movers: Alexion, Arena, Novavax

Biotech Movers: Alexion, Arena, Novavax

Alexion, Arena and Novavax were among the biotech stock movers ahead of the market open on Friday, July 7.

Alexion Reaches Funding Agreement With NICE And NHS England For Strensiq® (asfotase Alfa) For Patients With Pediatric-onset Hypophosphatasia (HPP)

Alexion Reaches Funding Agreement With NICE And NHS England For Strensiq® (asfotase Alfa) For Patients With Pediatric-onset Hypophosphatasia (HPP)

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that it has reached a national funding agreement with the National Institute for Health and Care Excellence (NICE) and the National Health Service (NHS) England...

Who's Afraid of the Amazon Empire?: Cramer's 'Mad Money' Recap (Thursday 6/22/17)

Who's Afraid of the Amazon Empire?: Cramer's 'Mad Money' Recap (Thursday 6/22/17)

Jim Cramer doesn't buy the backlash against Amazon. He says Prime is a very powerful tool and an irresistible bargain.

Alexion Receives Positive CHMP Opinion For Soliris® (Eculizumab) For The Treatment Of Patients With Refractory Generalized Myasthenia Gravis (gMG) In The European Union

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to extend the current...

Citigroup, Zoetis, AbbVie, Mattel, Valeant Pharmaceuticals 'Mad Money' Lightning Round

Citigroup, Zoetis, AbbVie, Mattel, Valeant Pharmaceuticals 'Mad Money' Lightning Round

Jim Cramer is bullish on Citigroup, Zoetis, Idexx Labs, AbbVie, Nucor, and Alexion.

TheStreet Quant Rating: B- (Buy)